Signals, Powered By EquityPandit
Lupin has got the approval from the US health regulator for marketing its Flucytosine capsules that are used in treating fungal infections.
Lupin has said in a statement that the company has received final approval for marketing its Flucytosine capsules USP, in the strengths of 250 mg and 500 mg, from the United States Food and Drug Administration (USFDA).
It added that the product is generic version of Valeant Pharmaceuticals International Inc’s Ancobon capsules in the same strengths.
